China Biologic Products, Inc. (NASDAQ:CBPO) has earned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.
Analysts have set a one year consensus target price of $131.67 for the company and are forecasting that the company will post $1.30 EPS for the current quarter, according to Zacks. Zacks has also assigned China Biologic Products an industry rank of 93 out of 265 based on the ratings given to related companies.
A number of analysts have recently issued reports on the stock. Jefferies Group LLC reissued a “buy” rating on shares of China Biologic Products in a research report on Friday, August 4th. BidaskClub lowered shares of China Biologic Products from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Zacks Investment Research lowered shares of China Biologic Products from a “hold” rating to a “sell” rating in a research report on Monday, August 7th. Finally, Goldman Sachs Group, Inc. (The) began coverage on shares of China Biologic Products in a research report on Tuesday, May 30th. They set a “neutral” rating on the stock.
A number of institutional investors and hedge funds have recently modified their holdings of CBPO. Oppenheimer Asset Management Inc. bought a new position in China Biologic Products during the first quarter valued at approximately $156,000. Nomura Holdings Inc. bought a new position in China Biologic Products during the first quarter valued at approximately $463,000. Jennison Associates LLC raised its position in China Biologic Products by 0.8% during the second quarter. Jennison Associates LLC now owns 5,775 shares of the biopharmaceutical company’s stock valued at $653,000 after acquiring an additional 44 shares in the last quarter. AHL Partners LLP bought a new position in China Biologic Products during the second quarter valued at approximately $842,000. Finally, First Trust Advisors LP raised its position in China Biologic Products by 35.9% during the first quarter. First Trust Advisors LP now owns 11,561 shares of the biopharmaceutical company’s stock valued at $1,158,000 after acquiring an additional 3,053 shares in the last quarter. 72.82% of the stock is currently owned by hedge funds and other institutional investors.
China Biologic Products (NASDAQ:CBPO) traded up 2.24% during midday trading on Wednesday, reaching $92.80. 120,927 shares of the company’s stock traded hands. China Biologic Products has a 52 week low of $88.25 and a 52 week high of $126.47. The stock has a market capitalization of $2.53 billion, a price-to-earnings ratio of 24.15 and a beta of 1.75. The company’s 50-day moving average price is $93.20 and its 200 day moving average price is $104.03.
China Biologic Products (NASDAQ:CBPO) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.05. The business had revenue of $89.28 million during the quarter, compared to analyst estimates of $97.33 million. China Biologic Products had a net margin of 31.55% and a return on equity of 21.86%. The firm’s revenue was down 2.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.26 earnings per share. On average, equities research analysts expect that China Biologic Products will post $4.96 earnings per share for the current year.
China Biologic Products Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.